Tetra Bio-Pharma Inc. announced that Health Canada has granted two Drug Identification Numbers for the first over-the-counter products to be marketed under its TERPACAN banner. Tetra is in the process of finalizing supply, sales and distribution agreements with several companies, and anticipates launching TERPACAN products in Canadian pharmacy retail outlets by mid-2020. Additionally, Tetra will launch these products into the American and European markets in 2020, once it receives final marketing authorization in those countries. In preparation for a late 2020 launch in the United States, Tetra is in the process of finalizing a supply agreement with a contract manufacturer to establish manufacturing, and obtaining a National Drug Code number for each drug, a requirement for all OTC drugs sold in the United States. TERPACAN (hemorrhoids) is a topical formulation that will be used for the treatment of hemorrhoids, an itchy, painful and common condition affecting thousands of Canadians. TERPACAN (back & muscle pain) is indicated for the temporary relief of aches and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains, arthritic or rheumatic pain and pain of tendons and ligaments. In Canada the hemorrhoid treatment market has reached $22 million, posting a steady 3% CAGR in 2019 while the highly competitive self-care pain treatment market has reached $432 million, posting a 1% CAGR1.